Health Care
The dispersion inside one sector. Sector momentum picks where; this is which — and the spread within a sector is wider than the spread between them.
Rank by
Within one sector these rank identically — relative strength is the raw return minus a constant (the sector median), so it cannot change the order. The toggle leads with the number you chose. To see the two axes diverge, use the whole-market view.
Worst by vs sector — 50
Return minus the sector’s own median — the discriminator. Showing names that trade at least $1M/day — the tradeable floor. For the untradeable end of the market, see the red list, where the floor comes off.
| # | Company | Raw 12m | vs sector | Capital | $/day |
|---|---|---|---|---|---|
| 1 | SPRBSpruce Biosciences, Inc. - Common Stock | -91.6% | -91.6% | Not computable | $1.8M |
| 2 | ATYRaTyr Pharma, Inc. - Common Stock | -90.9% | -90.8% | Shrinking | $2.8M |
| 3 | GOSSGossamer Bio, Inc. - Common Stock | -90.6% | -90.5% | Not computable | $5.4M |
| 4 | STEXStreamex Corp. - Common Stock | -84.6% | -84.5% | Not computable | $3.1M |
| 5 | LENZLENZ Therapeutics, Inc. - Common Stock | -84.5% | -84.4% | Not computable | $11.0M |
| 6 | QNTMQuantum Biopharma Ltd. - Class B Subordinate Voting Shares | -83.2% | -83.1% | — | $1.1M |
| 7 | MENSJyong Biotech Ltd. - Ordinary shares | -81.0% | -80.9% | — | $1.1M |
| 8 | HRTXHeron Therapeutics, Inc. - Common Stock | -80.2% | -80.1% | Not computable | $1.8M |
| 9 | NNOXNANO-X IMAGING LTD - Ordinary Shares | -79.6% | -79.5% | — | $3.6M |
| 10 | AVXLAnavex Life Sciences Corp. - Common Stock | -79.5% | -79.4% | Not computable | $6.6M |
| 11 | OMOutset Medical, Inc. - Common Stock | -76.8% | -76.7% | Harvesting | $1.8M |
| 12 | HYPDHyperion DeFi, Inc. - Common Stock | -75.3% | -75.2% | Not computable | $2.0M |
| 13 | TNXPTonix Pharmaceuticals Holding Corp. - Common Stock | -72.6% | -72.5% | Shrinking | $10.5M |
| 14 | HUMAHumacyte, Inc. - Common Stock | -72.0% | -71.9% | Not computable | $6.1M |
| 15 | NAGENiagen Bioscience, Inc. - Common Stock | -69.2% | -69.1% | Compounding | $6.1M |
| 16 | SNWVSANUWAVE Health, Inc. - Common Stock | -68.9% | -68.8% | Not computable | $1.5M |
| 17 | EMBCEmbecta Corp. - Common Stock | -67.8% | -67.7% | Diluting | $6.5M |
| 18 | CRDFCardiff Oncology, Inc. - Common Stock | -67.3% | -67.2% | Shrinking | $1.8M |
| 19 | QCLSQ/C Technologies, Inc. - Common Stock | -66.4% | -66.3% | Harvesting | $1.4M |
| 20 | RGCRegencell Bioscience Holdings Limited - Ordinary Shares | -65.6% | -65.5% | — | $3.6M |
| 21 | AKBAAkebia Therapeutics, Inc. - Common Stock | -65.2% | -65.2% | Not computable | $6.7M |
| 22 | PRCTPROCEPT BioRobotics Corporation - Common Stock | -63.5% | -63.4% | Diluting | $37.3M |
| 23 | ADCTADC Therapeutics SA Common Shares | -62.7% | -62.6% | Not computable | $2.6M |
| 24 | VORVor Biopharma Inc. - Common Stock | -62.3% | -62.2% | Not computable | $10.7M |
| 25 | ALVOAlvotech - Ordinary Shares | -62.0% | -61.9% | — | $2.2M |
| 26 | ALDXAldeyra Therapeutics, Inc. - Common Stock | -61.5% | -61.4% | Not computable | $3.5M |
| 27 | PRGOPerrigo Company plc Ordinary Shares | -60.6% | -60.5% | Shrinking | $31.9M |
| 28 | INSPInspire Medical Systems, Inc. Common Stock | -60.6% | -60.5% | Compounding | $72.4M |
| 29 | MLTXMoonLake Immunotherapeutics - Class A Ordinary Shares | -59.9% | -59.8% | Diluting | $20.4M |
| 30 | LFMDLifeMD, Inc. - Common Stock | -58.0% | -57.9% | Not computable | $5.3M |
| 31 | BSXBoston Scientific Corporation Common Stock | -57.2% | -57.1% | Compounding | $850.1M |
| 32 | SPRYARS Pharmaceuticals, Inc. - Common Stock | -56.8% | -56.7% | Diluting | $16.6M |
| 33 | PROKProKidney Corp. - Class A Ordinary Shares | -56.4% | -56.3% | Not computable | $2.2M |
| 34 | FULCFulcrum Therapeutics, Inc. - Common Stock | -55.2% | -55.1% | Harvesting | $5.4M |
| 35 | STIMNeuronetics, Inc. - Common Stock | -53.6% | -53.5% | Compounding | $2.7M |
| 36 | IXHLIncannex Healthcare Inc. - Common Stock | -53.2% | -53.2% | Not computable | $3.1M |
| 37 | ADMAADMA Biologics Inc - Common Stock | -52.0% | -51.9% | Compounding | $46.8M |
| 38 | GUTSFractyl Health, Inc. - Common Stock | -51.5% | -51.4% | Not computable | $1.2M |
| 39 | PSTVPLUS THERAPEUTICS, Inc. - Common Stock | -50.9% | -50.9% | Not computable | $2.0M |
| 40 | ZTSZoetis Inc. Class A Common Stock | -50.8% | -50.7% | Compounding | $473.9M |
| 41 | AARDAardvark Therapeutics, Inc. - Common Stock | -50.8% | -50.7% | Not computable | $1.1M |
| 42 | ARCTArcturus Therapeutics Holdings Inc. - Common Stock | -49.6% | -49.5% | Not computable | $4.4M |
| 43 | ORGOOrganogenesis Holdings Inc. - Class A | -49.4% | -49.4% | Compounding | $2.8M |
| 44 | LFVNLifevantage Corporation - Common Stock | -48.7% | -48.6% | Compounding | $1.1M |
| 45 | FLNAFilana Therapeutics, Inc. - Common Stock | -46.8% | -46.7% | Not computable | $1.4M |
| 46 | PODDInsulet Corporation - Common Stock | -44.5% | -44.4% | Compounding | $211.9M |
| 47 | ENGNenGene Therapeutics Inc. - Common Stock | -44.3% | -44.2% | Not computable | $1.4M |
| 48 | LFCRLifecore Biomedical, Inc. - Common Stock | -43.3% | -43.2% | Not computable | $1.0M |
| 49 | ACBAurora Cannabis Inc. - Common Shares | -41.7% | -41.6% | — | $3.9M |
| 50 | XGNExagen Inc. - Common Stock | -41.4% | -41.4% | Harvesting | $1.5M |
What the badges mean
Capital state — what the company is doing with its money
- Compounding
- Capital base growing AND profit growing — deploying money and earning a return on it. NVDA, COST, KLAC.
- Harvesting
- Capital base shrinking via buybacks or deleveraging while profit GROWS. Healthy — Apple, GE. Blue, never a warning colour, and never on the red list.
- Diluting
- Pouring more capital into falling profit — growing revenue while destroying value. INTC, PFE. Red-list eligible.
- Shrinking
- Capital base AND profit both collapsing — the business is evaporating. Fossil, Lumen. Red-list eligible.
- Not computable
- Computed, and there is genuinely not enough filing history to place it. An absence, not a verdict — and distinct from “not computed”, which means we never ran leg 3 for that row at all.
Share class — the row is one company, which may list several classes
- +1
- This company lists N more common classes than the one shown (GOOG/GOOGL, LEN/LEN.B). The row is company-level; the visible ticker is just the label we sort under. The return is priced off the most LIQUID class, not the alphabetically first — hover to see which.
- basis?
- This multi-class company has no volume data, so we cannot say which class priced its return. We do NOT fall back to the first listing — that fallback is the bug that once made a return a fact about the alphabet. Treat this row’s relative strength as unverified.